A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Cathie Wood, Ark Investment’s chief executive, has said that the "most underappreciated application of AI" is health care.

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

BofA raised the firm’s price target on Tempus AI (TEM) to $60 from $54 and keeps a Neutral rating on the shares after the company reported Q4 ...

The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Q4 2024 Earnings Call Transcript February 24, 2025 Tempus AI, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.15. Operator: Thank you for standing by. My name ...

Tempus posted a fourth-quarter adjusted net loss of $0.18 per share, $0.02 more per share than estimates by analysts surveyed ...

We recently published a list of 10 AI Stocks on Analysts’ Radar As AI Spending Grows. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other AI ...

CompanyOverview\|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an emerging AI player in the healthcare field with a robust outlook ...